BACKGROUND:Artemisinin-based combination therapy (ACT) has become the standard of care for the treatment of uncomplicated Plasmodium falciparum malaria. Although several ACT regimens are approved, data guiding optimal choices of ACTs are limited. We compared short- and long-term outcomes in a cohort of young Ugandan children randomized to 2 leading ACTs. METHODS: Overall, 312 children were randomized to artemether-lumefantrine or dihydroartemisinin-piperaquine (DP) at the time of the first episode of uncomplicated malaria (median age, 10.5 months). The same treatment was given for all subsequent episodes of uncomplicated malaria and children were followed until they reached 5 years of age. The cohort included a subgroup that was human immunodeficiency virus (HIV) infected (n = 44) or HIV exposed (n = 175) and prescribedtrimethoprim-sulfamethoxazole (TMP-SMX) prophylaxis. Outcomes included time to recurrent malaria following individual treatments and the overall incidences of treatments for malaria, complicated malaria, and hospitalizations. RESULTS: Among children not prescribed TMP-SMX prophylaxis, 4443 treatments for malaria were given over 790 person-years following randomization. Treatment with DP was associated with a lower hazard of recurrent malaria over the 84 days after treatment (hazard ratio, 0.66; 95% confidence interval [CI], .61-.70; P < .001). Children randomized to DP had a lower incidence of all treatments for malaria (incidence rate ratio [IRR], 0.85; 95% CI, .75-.96; P = .01), complicated malaria (IRR, 0.12; 95% CI, .04-.39; P < .001), and hospitalizations (IRR, 0.31; 95% CI, .13-.77; P = .01). Among children prescribed TMP-SMX prophylaxis, there were no significant differences in longitudinal outcomes. CONCLUSIONS: Compared to artemether-lumefantrine, the use of DP to treat uncomplicated malaria delayed the time to recurrent malaria and reduced the incidences of treatments for malaria, complicated malaria, and hospitalizations. CLINICAL TRIALS REGISTRATION: NCT00527800.
RCT Entities:
BACKGROUND:Artemisinin-based combination therapy (ACT) has become the standard of care for the treatment of uncomplicated Plasmodium falciparum malaria. Although several ACT regimens are approved, data guiding optimal choices of ACTs are limited. We compared short- and long-term outcomes in a cohort of young Ugandan children randomized to 2 leading ACTs. METHODS: Overall, 312 children were randomized to artemether-lumefantrine or dihydroartemisinin-piperaquine (DP) at the time of the first episode of uncomplicated malaria (median age, 10.5 months). The same treatment was given for all subsequent episodes of uncomplicated malaria and children were followed until they reached 5 years of age. The cohort included a subgroup that was human immunodeficiency virus (HIV) infected (n = 44) or HIV exposed (n = 175) and prescribed trimethoprim-sulfamethoxazole (TMP-SMX) prophylaxis. Outcomes included time to recurrent malaria following individual treatments and the overall incidences of treatments for malaria, complicated malaria, and hospitalizations. RESULTS: Among children not prescribed TMP-SMX prophylaxis, 4443 treatments for malaria were given over 790 person-years following randomization. Treatment with DP was associated with a lower hazard of recurrent malaria over the 84 days after treatment (hazard ratio, 0.66; 95% confidence interval [CI], .61-.70; P < .001). Children randomized to DP had a lower incidence of all treatments for malaria (incidence rate ratio [IRR], 0.85; 95% CI, .75-.96; P = .01), complicated malaria (IRR, 0.12; 95% CI, .04-.39; P < .001), and hospitalizations (IRR, 0.31; 95% CI, .13-.77; P = .01). Among children prescribed TMP-SMX prophylaxis, there were no significant differences in longitudinal outcomes. CONCLUSIONS: Compared to artemether-lumefantrine, the use of DP to treat uncomplicated malaria delayed the time to recurrent malaria and reduced the incidences of treatments for malaria, complicated malaria, and hospitalizations. CLINICAL TRIALS REGISTRATION: NCT00527800.
Authors: Isabel Rodriguez-Barraquer; Emmanuel Arinaitwe; Prasanna Jagannathan; Michelle J Boyle; Jordan Tappero; Mary Muhindo; Moses R Kamya; Grant Dorsey; Chris Drakeley; Isaac Ssewanyana; David L Smith; Bryan Greenhouse Journal: J Infect Dis Date: 2016-08-01 Impact factor: 5.226
Authors: Melissa D Conrad; Norbert LeClair; Emmanuel Arinaitwe; Humphrey Wanzira; Abel Kakuru; Victor Bigira; Mary Muhindo; Moses R Kamya; Jordan W Tappero; Bryan Greenhouse; Grant Dorsey; Philip J Rosenthal Journal: J Infect Dis Date: 2014-03-08 Impact factor: 5.226
Authors: Patrick Tumwebaze; Melissa D Conrad; Andrew Walakira; Norbert LeClair; Oswald Byaruhanga; Christine Nakazibwe; Benjamin Kozak; Jessica Bloome; Jaffer Okiring; Abel Kakuru; Victor Bigira; James Kapisi; Jennifer Legac; Jiri Gut; Roland A Cooper; Moses R Kamya; Diane V Havlir; Grant Dorsey; Bryan Greenhouse; Samuel L Nsobya; Philip J Rosenthal Journal: Antimicrob Agents Chemother Date: 2015-03-09 Impact factor: 5.191
Authors: Danica A Helb; Kevin K A Tetteh; Philip L Felgner; Jeff Skinner; Alan Hubbard; Emmanuel Arinaitwe; Harriet Mayanja-Kizza; Isaac Ssewanyana; Moses R Kamya; James G Beeson; Jordan Tappero; David L Smith; Peter D Crompton; Philip J Rosenthal; Grant Dorsey; Christopher J Drakeley; Bryan Greenhouse Journal: Proc Natl Acad Sci U S A Date: 2015-07-27 Impact factor: 11.205
Authors: Prasanna Jagannathan; Charlie C Kim; Bryan Greenhouse; Felistas Nankya; Katherine Bowen; Ijeoma Eccles-James; Mary K Muhindo; Emmanuel Arinaitwe; Jordan W Tappero; Moses R Kamya; Grant Dorsey; Margaret E Feeney Journal: Sci Transl Med Date: 2014-08-27 Impact factor: 17.956
Authors: Sally Peprah; Constance Tenge; Isaiah O Genga; Mediatrix Mumia; Pamela A Were; Robert T Kuremu; Walter N Wekesa; Peter O Sumba; Tobias Kinyera; Isaac Otim; Ismail D Legason; Joshua Biddle; Steven J Reynolds; Ambrose O Talisuna; Robert J Biggar; Kishor Bhatia; James J Goedert; Ruth M Pfeiffer; Sam M Mbulaiteye Journal: Am J Trop Med Hyg Date: 2019-01 Impact factor: 2.345